FDA places ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) on speedier review-path

Boston, MA 04/12/2013 (wallstreetpr) – A biotechnology company ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) (Current: $12.83, Down by 2.14%), which has annual sales of $5 million ascended by 43 percent after it said that its lead drug will gain U.S regulatory review prior to its anticipated time. Through yesterday, its shares rose five-fold in 12 months. By the end of 2014, the San Diego-based company plans on applying for a review by the Food and Drug Administration of its drug pimavanserin. Later this month, a final-phase trial was to be conducted. The company said that the FDA has agreed that Acadia will not have to conduct that particular trial.

Speedier trial
Pimavanserin is to be used for the treatment of Parkinson’s disease psychosis. Instead of the scheduled review, Acadia can now use supportive data and trial results from the various other studies that have been conducted and then seek a review of the drug. In a statement, the Chief Executive Officer of the company, Uli Hacksell said that the company is very pleased with the way the talks with the Food Drug Administration authorities progressed and the outcome has been very conducive to the company as well. This will go a long way in reducing the time and the costs associated with the PDP development program.

Progressive deterioration
Parkinson’s disease or PD is a chronic in nature. The disorder has progressive movement. This means that the symptoms not only continue but tend to worsen over a period of time. Over one million people in the U.S suffer from the disease that has no solid cure as of now and its symptoms are largely managed with medication. Acadia’s once-a-day pill primavanserin is under trial. The study that is being conducted is for the treatment of loss of contact with the real world and more often than not is accompanied by hallucinations.

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.